Intermittent vs Continous infusion of colistin in VAP
Not Applicable
- Conditions
- Health Condition 1: J159- Unspecified bacterial pneumonia
- Registration Number
- CTRI/2019/04/018847
- Lead Sponsor
- dr simranpreet singh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Children of age 1 month to 18yrs suffering from VAP as per CPIS score and microbiological evidence of gram negative organism in culture specimen
Exclusion Criteria
any patient with gram positive organism growth or sensitivity to a lower class of antibiotic. Also patients who leave against medical advice or those with untimely mortality during study duration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of colistin in treating ventilator-associated pneumonia (VAP) in PICU patients?
How does continuous infusion of colistin compare to intermittent dosing in efficacy for J159 bacterial pneumonia treatment?
What biomarkers could predict response to colistin infusion strategies in critically ill pediatric patients with VAP?
What adverse events are associated with continuous versus intermittent colistin administration in ICU settings?
Are there combination therapies or alternative drugs showing better outcomes than colistin for multidrug-resistant VAP in PICU?